School of Medicine
Showing 1-5 of 5 Results
Professor of Pediatrics (Hematology/Oncology) and of Medicine
Current Research and Scholarly Interests Recent clinical studies, by us and others, have demonstrated that T cell based immunotherapy can eradicate cancers resistant to all other available therapies. Our program is focused on using genetically engineered T cells to treat cancer. We link the bench with the bedside, developing novel therapies for early phase testing in clinical trials, will simultaneously conducting intensive studies on clinical samples obtained from patients treated on immunotherapy trials.
Everett Meyer, M.D., Ph.D.
Assistant Professor of Medicine (Blood and Marrow Transplantation) at the Stanford University Medical Center
Current Research and Scholarly Interests Research focus in T cell immunotherapy and T cell immune monitoring using high-throughput sequencing and genomic approaches, with an emphasis on hematopoietic stem cell transplantation, the treatment of graft-versus-host disease and immune tolerance induction.
David Miklos, M.D., Ph.D.
Associate Professor of Medicine (Blood and Marrow Transplantation) at the Stanford University Medical Center
Current Research and Scholarly Interests Dr. Miklos is the Clinical Director of Stanford University’s Center for Cancer Cell Therapy, and leads Stanford’s CAR therapy clinical trials for patients with aggressive lymphomas: 1) Phase I CAR19-22 Safety and efficacy outcomes – the first bispecific CAR-T study for patients with rel/refractory DLBCL and ALL, 2) CAR19 CD4-CD8 immune phenotyping following various CAR-T, 3) Mechanisms for CAR-T DLBCL treatment Failure
Lori Muffly, MD, MS
Assistant Professor of Medicine (Bone and Marrow Transplantation) at the Stanford University Medical Center
Current Research and Scholarly Interests Dr. Muffly's interests include health services research and clinical trials with a focus on acute leukemia and blood and marrow transplantation.